Venture Certified
| 기술평가대출기업(중진공) | 2020-04-20 ~ 2022-04-19 | 20200400787 | 2020-04-20 |
| 벤처투자유형 | 2022-04-20 ~ 2025-04-19 | 20220504010017 | 2020-04-20 |
| 벤처투자유형 | 2025-04-20 ~ 2028-04-19 | 20250319010006 | 2020-04-20 |
| Item | 2023 | 2022 |
|---|---|---|
| Revenue | 0.0B | 0.0B |
| Operating Profit | -20B | -12B |
| Net Profit | -19B | -12B |
| Total Assets | 49B | 50B |
| Total Liabilities | 24B | 5.8B |
| Total Equity | 25B | 44B |
Operating Loss: Op. profit -20B
2 Consecutive Years of Net Loss
Debt Ratio Surge (+81pp YoY)
- 0.0%
▼ 67.8%
▲ 616.8%
▼ 181.1%
| Name | Position | Role |
|---|---|---|
| 김선택 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "세종특별자치시 조치원읍",
"ceo_name": "김선택",
"certificate": [
{
"cert_number": "20200400787",
"changes": "",
"disclosure_date": "2020-04-20",
"first_cert_date": "2020-04-20",
"no": "1",
"type": "기술평가대출기업(중진공)",
"valid_period": "2020-04-20 ~ 2022-04-19"
},
{
"cert_number": "20220504010017",
"changes": "",
"disclosure_date": "2022-05-04",
"first_cert_date": "2020-04-20",
"no": "2",
"type": "벤처투자유형",
"valid_period": "2022-04-20 ~ 2025-04-19"
},
{
"cert_number": "20250319010006",
"changes": "",
"disclosure_date": "2025-03-19",
"first_cert_date": "2020-04-20",
"no": "3",
"type": "벤처투자유형",
"valid_period": "2025-04-20 ~ 2028-04-19"
}
],
"company_name": "티큐브잇 주식회사",
"corp_no": "164711-*******",
"financials": {
"2022": {
"capital_stock": 97263000,
"cost_of_sales": 0,
"current_assets": 4512362000,
"current_liabilities": 477895000,
"gross_profit": 0,
"net_income": -1152612000,
"net_income_bs": -1152612000,
"non_current_assets": 484527000,
"non_current_liabilities": 101890000,
"non_operating_expenses": 5646000,
"non_operating_income": 43092000,
"operating_profit": -1190058000,
"revenue": 0,
"sga_expenses": 1190058000,
"total_assets": 4996889000,
"total_equity": 4417103000,
"total_liabilities": 579786000
},
"2023": {
"capital_stock": 97263000,
"cost_of_sales": 0,
"current_assets": 4084188000,
"current_liabilities": 2328528000,
"gross_profit": 0,
"net_income": -1869062000,
"net_income_bs": -1869062000,
"non_current_assets": 861114000,
"non_current_liabilities": 68738000,
"non_operating_expenses": 31311000,
"non_operating_income": 159058000,
"operating_profit": -1996809000,
"revenue": 0,
"sga_expenses": 1996809000,
"total_assets": 4945302000,
"total_equity": 2548036000,
"total_liabilities": 2397266000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "1,002,924,000",
"changes": "1,002,924,000",
"date": "2022-08-26"
},
{
"amount": "1,002,924,000",
"changes": "1,002,924,000",
"date": "2022-08-26"
},
{
"amount": "800,000,000",
"changes": "800,000,000",
"date": "2020-09-08"
}
],
"main_products": "세포치료제",
"phone": "044-866-****",
"years": [
2023,
2022
]
}Data Quality: 7/10 | Primary Source: Venture System | Section Coverage: 6/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Not Collected | Not Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |